HIV Antiretroviral Therapy 2017: Clinical Controversies in When and What to Start
Rajesh T. Gandhi, MD
Associate Professor of Medicine, Harvard Medical School
Departments of Medicine and Infectious Diseases
Massachusetts General Hospital, Boston, MA
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2017. All rights reserved.
Raj Gandhi is the site leader of the Massachusetts General Hospital AIDS Clinical Research Site in the Harvard/Miriam AIDS Clinical Trials Unit (ACTU) and a member of the AIDS Clinical Trials Group HIV-1 Reservoirs and Eradication Transformative Science Group. He is also the Director of the Harvard University Center for AIDS Research (CFAR) Clinical Core. Dr. Gandhi is the editor of Partners ID Images, an educational infectious diseases website, and organizer of the HIV Online Provider Education (HOPE) program, which is an internet-based educational conference series for physicians caring for HIV-infected patients in resource-limited settings. He is also an Associate Editor of Journal Watch Infectious Diseases and Contributing Editor to Journal Watch HIV/AIDS Clinical Care. He is a scientific member of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. His research interests include clinical trials of immune-based therapies for HIV, HIV reservoirs, and HIV/viral hepatitis coinfections.
At the completion of this educational session, learners will:
- Be able to discuss the optimal timing of initiation of antiretroviral therapy in HIV-infected patients.
- Be able to summarize the latest recommendations for first-line antiretroviral regimens in HIV-infected patients.
- Be able to evaluate how to individualize the choice of an antiretroviral regimen based on a patient’s specific comorbidities and conditions.
This PRN CME activity is funded in part by unrestricted educational grants from:
Bristol-Myers Squibb, Gilead Sciences, Merck & Co, and ViiV Healthcare.
